RT Journal Article
SR Electronic
T1 Unraveling COVID-19-related hospital costs: The impact of clinical and demographic conditions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.24.20248633
DO 10.1101/2020.12.24.20248633
A1 Anna Miethke-Morais
A1 Alex Cassenote
A1 Heloísa Piva
A1 Eric Tokunaga
A1 Vilson Cobello
A1 Fábio Augusto Rodrigues Gonçalves
A1 Renata Aparecida dos Santos Lobo
A1 Evelinda Trindade
A1 Luiz Augusto Carneiro D‘Albuquerque
A1 Luciana Bertocco de Paiva Haddad
A1 on behalf of HCFMUSP Covid-19 Study Group
YR 2020
UL http://medrxiv.org/content/early/2020/12/30/2020.12.24.20248633.abstract
AB Introduction Although patients’ clinical conditions were previously shown to be associated with coronavirus disease 2019 (COVID-19) severity and outcomes, their impact on hospital costs is not known. The economic evaluation of COVID-19 admissions allows the assessment of hospital costs associated with the treatment of these patients, including the main cost components and costs driven by demographic and clinical conditions. The aim of this study was to determine the COVID-19 hospitalization-related costs and their association with clinical conditions.Methods Prospective observational cohort study of the hospitalization costs of patients with COVID-19 admitted between March 30 and June 30, 2020, who were followed until discharge, death, or external transfer, using micro-costing methodology. The study was carried out in the Central Institute of the Hospital das Clinicas, affiliated with the Faculty of Medicine of the University of Sao Paulo, Brazil, which is the largest hospital complex in Latin America and was designated to exclusively admit COVID-19 patients during the pandemic response.Results The average cost of the 3,254 admissions (51.7% of which involved intensive care unit (ICU) stays) was US$12,637.42. Overhead cost was the main cost component, followed by daily fixed costs and drugs. Sex, age and underlying hypertension (US$14,746.77), diabetes (US$15,002.12), obesity (US$18,941.55), cancer (US$10,315.06), chronic renal failure (US$15,377.84), and rheumatic (US$17,764.61), hematologic (US$15,908.25) and neurologic diseases (US$15,257.95) were significantly associated with higher costs. Age >69 years, RT-PCR-confirmed COVID-19, comorbidities, the use of mechanical ventilation, dialysis, or surgery, and poor outcomes remained significantly associated with higher costs after model adjustment.Conclusion Knowledge of COVID-19-associated hospital costs and their impact across different populations can aid in the development of a generalizable and comprehensive approach to hospital preparedness, decision-making and planning for future risk management. Determining the disease-associated costs is the first step in evaluating the cost-effectiveness of treatments and vaccination programs.Question What are the COVID-19 hospitalization-related costs?Findings In this prospective cohort that was carried out in a single reference quaternary center designated for the treatment of severe cases of COVID-19, more than three thousand patients were included, and their costs of hospitalization were found to be directly related to the age and comorbidities. The costs were more than 50% higher in older patients, 10-24% higher in patients with comorbidities, and 24-200% higher when additional therapeutic procedures were required.Meaning Determining the disease-associated costs is the first step in conducting future evaluations of the cost-effectiveness of treatments and vaccination programs, supporting their implementation with a comprehensive population-based approach.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was conducted without funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees whose project has been submitted and approved: CAPPESQ - Research Ethics Committee of the HC- Faculty of Medicine of the University of Sao Paulo (https://sgpcappesq.hc.fm.usp.br/) Plataforma Brasil (https://pl Plataformabrasil.saude.gov.br/login.jsf) . CAPPESQ approval number - CAAE 33924920.0.0000.0068. Document submitted as an attachment All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified participant data and a data dictionary defining each field in the set will be made available on request. They will be sent by the corresponding author after approval of a proposal with a signed data access agreement. Data will be available on publication.